Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 12 July 2017 | By Zachary Brennan
The US Food and Drug Administration (FDA) told Focus on Wednesday that the agency is considering labeling changes to include additional ocular inflammatory conditions for three immune checkpoint inhibitors.
Currently, the labels of Bristol-Myers Squibb’s Yervoy (ipilimumab), Opdivo (nivolumab) and Merck’s Keytruda (pembrolizumab) have uveitis listed as a potential immune-mediated adverse reaction (AR), and four of the five FDA-approved anti-PD1 therapies’ labels include uveitis.
The consideration for changing the labels of Yervoy, Opdivo and Keytruda comes as FDA says it has completed post-marketing reviews for sight-threatening complications such as retinal detachment and vision loss with the three treatments.
Tralisa Colby, an FDA public affairs specialist, explained to Focus: "Regulatory discussions are ongoing regarding PD-1 pathway blocking antibodies in attempts to improve the consistency and effectiveness of the information regarding immune-mediated ARs provided in the labels. Those labeling changes may include additional characterization of ocular inflammatory conditions; however, the current term, uveitis, should convey the severity and potential ocular complications to oncology physicians."
Ultimately, Colby said, the safety decision will be made in collaboration between FDA’s Office of Surveillance and Epidemiology and Office of New Drugs, with relevant discipline input across the agency as necessary.
Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS): January - March 2017
FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files
Tags: Opdivo, Keytruda, Yervoy, B-MS, Merck, uveitis
Regulatory Focus newsletters
All the biggest regulatory news and happenings.